News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Press releases

2019

16 October, 2019 PledPharma approved for listing on Nasdaq Stockholm News Corporate Action Other English Regulatory MAR IR Optional
9 October, 2019 PledPharma and Solasia enter a second license agreement for the development and commercialisation of PledOx® in Asia, targeting neuropathy caused by taxanes and any other chemotherapy News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-pledox
21 August, 2019 Half-Year report January-June 2019 News English Regulatory MAR Report Interim Q2 IR Optional
21 May, 2019 PledPharma completes a Directed New Share Issue of 4,866,665 shares, raising proceeds of SEK 91 million News Corporate Action Shares Issuance English Regulatory MAR IR Optional
21 May, 2019 PledPharma announces intention of a Directed New Share Issue News Corporate Action Shares Issuance English Regulatory MAR IR Optional
7 May, 2019 Report from the Annual General Meeting of PledPharma News Corporate Information General meeting Report of the AGM English Regulatory Listing Regulation IR Optional
6 May, 2019 Interim report January-March 2019 News English Regulatory MAR Report Interim Q1 IR Optional
8 April, 2019 NOTICE OF ANNUAL GENERAL MEETING OF PLEDPHARMA AB News Corporate Information General meeting Notice English Regulatory Listing Regulation IR Optional
8 April, 2019 PledPharma’s 2018 annual report published News English Regulatory Listing Regulation Report Annual IR Optional
18 March, 2019 PledPharma’s drug candidate Aladote® granted Orphan Drug Designation News Corporate Action Other English Regulatory MAR IR Optional mfn-cus-aladote
21 February, 2019 Year-end Report January-December 2018 News English Regulatory MAR Report Interim Yearend IR Optional mfn-cus-aladote mfn-cus-pledox
31 January, 2019 Aladote®’s data has been selected for presentation at The International Liver Congress News English Regulatory IR Optional
17 January, 2019 PledPharma presents PledOx®’s phase III program at the Gastrointestinal (GI) Cancers Symposium News English Regulatory IR Optional
10 January, 2019 First Asian patient has been included in the global Phase III program for PledOx® and will trigger a milestone payment of 600 MJPY (c.49 MSEK) to PledPharma News English Regulatory IR Optional

2018

24 December, 2018 PledPharma applies for an Orphan Drug Designation (ODD) in the US for Aladote News English Regulatory IR Optional
13 December, 2018 PledPharma presents results from study on drug candidate Aladote® for paracetamol poisoning at a global toxicology conference News English Regulatory IR Optional
5 December, 2018 PledPharma prepares for listing on the Nasdaq Stockholm main market during 2019 News English Regulatory IR Optional
8 November, 2018 The first patient included in PledPharma’s global Phase III program for PledOx® News English Regulatory IR Optional
26 October, 2018 Nomination Committee appointed for the 2019 Annual General Meeting in PledPharma News English Regulatory IR Optional
23 October, 2018 Interim Report January-September 2018 News English Regulatory MAR Report Interim Q3 IR Optional
28 September, 2018 Study drug for the PledOx® global phase III program delivered News English Regulatory IR Optional
24 September, 2018 Pledpharma announces positive results from the Aladote® proof of principle study News English Regulatory IR Optional
22 August, 2018 Half-Year Report January-June 2018 News English Regulatory MAR Report Interim Q2 IR Optional
15 August, 2018 Delivery of study drug to the PledOx® phase III program is expected in September News English Regulatory IR Optional
24 April, 2018 Interim Report January-March 2018 News English Regulatory MAR Report Interim Q1 IR Optional
PreviousNext

Calendar and upcoming reports

November 8, 2024
Interim Report Q3 2024 (7:00am CET)

Show more events

Share

Twitter
LinkedIn

Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10

E-mail: [email protected]